Guengerich FP. Cytochrome P450S and other enzymes in drug metabolism and toxicity.
AAPS J 2006;8:E101–E111.
Hawkins DR. Use and value of metabolism databases. Drug Discov Today 1999;4:466–
471.
Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailability is
related to the extent of absorption: implications for bioavailability and bioequiva-
lence studies. Clin Pharmacol Ther 1996;60:601–607.
Houston JB, Carlile DJ. Prediction of hepatic clearance from microsomes, hepatocytes,
and liver slices. Drug Metab Rev 1997;29:891–922.
Houston JB, Kenworthy KE.In vitro–in vivoscaling of CYP kinetic data not consistent
with the classical Michaelis–Menten model. Drug Metab Dispos 2000;28:246–254.
Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. Quantitative prediction
ofin vivo drug clearance and drug interactions from in vitrodata on meta-
bolism, together with binding and transport. Annu Rev Pharmacol Toxicol 1998;
38:461–499.
Jones JP, Mysinger M, Korzekwa, KR. Computational models for cytochrome P450:a
predictive electronic model for aromatic oxidation and hydrogen atom abstraction.
Drug Metab Dispos 2002;30:7–12.
Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: reactive metabolite
formation, protein binding and the regulation of the immune system. Curr Drug
Metab 2002;3:367–377.
Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4:489–
499.
Kim HJ, Cho JH, Klaassen CD. Depletion of hepatic 3’-phosphoadenosine 5’-
phosphosulfate (PAPS) and sulfate in rats by xenobiotics that are sulfated. J
Pharmacol Exp Ther 1995;275:654–658.
Lau YY, Sapidou E, Cui X, White RE, Cheng, KC. Development of a novelin vitro
model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured
hepatocytes. Drug Metab Dispos 2002;30:1446–1454.
Lave T, Coassolo P, Reigner B. Prediction of hepatic metabolic clearance based on
interspecies allometric scaling techniques andin vitro–in vivocorrelations. Clin
Pharmacokinet 1999;36:211–231.
Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P. Integration ofin vitrodata
into allometric scaling to predict hepatic metabolic clearance in man: application to
10 extensively metabolized drugs. J Pharm Sci 1997;86:584–590.
Lave T, Luttringer O, Zuegge J, Schneider G, Coassolo P, Theil FP. Prediction of
human pharmacokinetics based on preclinicalin vitroandin vivodata. Ernst Schering
Res Found Workshop 2002;81–104
Lecoeur S, Bonierbale E, Challine D, Gautier JC, Valadon P, Dansette PM, Catinot R,
Ballet F, Mansuy D, Beaune PH. Specificity ofin vitrocovalent binding of tienilic
acid metabolites to human liver microsomes in relationship to the type of
hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem Res
Toxicol 1994;7:434–442.
Lewis DF. Quantitative structure–activity relationships (QSARs) within the cytochrome
P450 system: QSARs describing substrate binding, inhibition and induction of P450s.
Inflammopharmacology 2003;11:43–73.
256 DRUG METABOLISM RESEARCH